These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 23992319)

  • 1. Target therapies in pancreatic carcinoma.
    Silvestris N; Gnoni A; Brunetti AE; Vincenti L; Santini D; Tonini G; Merchionne F; Maiello E; Lorusso V; Nardulli P; Azzariti A; Reni M
    Curr Med Chem; 2014; 21(8):948-65. PubMed ID: 23992319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New therapeutic directions for advanced pancreatic cancer: targeting the epidermal growth factor and vascular endothelial growth factor pathways.
    Burris H; Rocha-Lima C
    Oncologist; 2008 Mar; 13(3):289-98. PubMed ID: 18378539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EGFR as a potential target for the treatment of pancreatic cancer: dilemma and controversies.
    Nedaeinia R; Avan A; Manian M; Salehi R; Ghayour-Mobarhan M
    Curr Drug Targets; 2014; 15(14):1293-301. PubMed ID: 25429712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular targeted therapies in the management of head and neck squamous cell carcinoma: recent developments and perspectives.
    Bozec A; Peyrade F; Milano G
    Anticancer Agents Med Chem; 2013 Mar; 13(3):389-402. PubMed ID: 23092267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Erlotinib: the first biologic in the management of pancreatic cancer.
    Saif MW
    Expert Opin Pharmacother; 2008 Jun; 9(9):1595-607. PubMed ID: 18518788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overview of Current Treatment Options and Investigational Targeted Therapies for Locally Advanced Squamous Cell Carcinoma of the Head and Neck.
    Zibelman M; Mehra R
    Am J Clin Oncol; 2016 Aug; 39(4):396-406. PubMed ID: 26967327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting EGFR in pancreatic cancer treatment.
    Troiani T; Martinelli E; Capasso A; Morgillo F; Orditura M; De Vita F; Ciardiello F
    Curr Drug Targets; 2012 Jun; 13(6):802-10. PubMed ID: 22458527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Recent update of molecular targeted therapy in pancreatic cancer].
    Cho JH
    Korean J Gastroenterol; 2013 Mar; 61(3):147-54. PubMed ID: 23575233
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular targeted therapy for pancreatic adenocarcinoma: A review of completed and ongoing late phase clinical trials.
    Mosquera C; Maglic D; Zervos EE
    Cancer Genet; 2016 Dec; 209(12):567-581. PubMed ID: 27613577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human pancreatic cancer stem cells are sensitive to dual inhibition of IGF-IR and ErbB receptors.
    Urtasun N; Vidal-Pla A; Pérez-Torras S; Mazo A
    BMC Cancer; 2015 Apr; 15():223. PubMed ID: 25886138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stromal depletion goes on trial in pancreatic cancer.
    Garber K
    J Natl Cancer Inst; 2010 Apr; 102(7):448-50. PubMed ID: 20339135
    [No Abstract]   [Full Text] [Related]  

  • 12. mTOR inhibition induces EGFR feedback activation in association with its resistance to human pancreatic cancer.
    Wei F; Zhang Y; Geng L; Zhang P; Wang G; Liu Y
    Int J Mol Sci; 2015 Feb; 16(2):3267-82. PubMed ID: 25654224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Molecular-based treatment concepts in advanced pancreatic cancer].
    Boeck S; Moosmann N; Stemmler HJ; Heinemann V
    Dtsch Med Wochenschr; 2007 Apr; 132(15):818-22. PubMed ID: 17427093
    [No Abstract]   [Full Text] [Related]  

  • 14. Molecularly targeted therapies in metastatic pancreatic cancer: a systematic review.
    Zagouri F; Sergentanis TN; Chrysikos D; Zografos CG; Papadimitriou CA; Dimopoulos MA; Filipits M; Bartsch R
    Pancreas; 2013 Jul; 42(5):760-73. PubMed ID: 23774698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting Epidermal Growth Factor Receptor-Related Signaling Pathways in Pancreatic Cancer.
    Philip PA; Lutz MP
    Pancreas; 2015 Oct; 44(7):1046-52. PubMed ID: 26355547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I dose escalation study of capecitabine and erlotinib concurrent with radiation in locally advanced pancreatic cancer.
    Jiang Y; Mackley HB; Kimchi ET; Zhu J; Gusani N; Kaifi J; Staveley-O'Carroll KF; Belani CP
    Cancer Chemother Pharmacol; 2014 Jul; 74(1):205-10. PubMed ID: 24908435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Agents targeting the Hedgehog pathway for pancreatic cancer treatment.
    Bisht S; Brossart P; Maitra A; Feldmann G
    Curr Opin Investig Drugs; 2010 Dec; 11(12):1387-98. PubMed ID: 21154121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Smarter drugs emerging in pancreatic cancer therapy.
    Kleger A; Perkhofer L; Seufferlein T
    Ann Oncol; 2014 Jul; 25(7):1260-1270. PubMed ID: 24631947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advanced stage pancreatic cancer: novel therapeutic options.
    Saif MW
    Expert Rev Clin Pharmacol; 2014 Jul; 7(4):487-98. PubMed ID: 24939470
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted therapy for the treatment of non-small cell lung cancer: focus on inhibition of epidermal growth factor receptor.
    Harichand-Herdt S; Ramalingam SS
    Semin Thorac Cardiovasc Surg; 2008; 20(3):217-23. PubMed ID: 19038731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.